Skip to main content
Clinical Trials/CTRI/2022/03/040921
CTRI/2022/03/040921
Active, not recruiting
未知

A ProSpective, multicentre, registry to evalUate the Clinical outCome of Encruso RAL-EverolimusEluting Coronary Stent System in real world percutaneOus coronary revasculaRization in Indian population- SUCCESSOR - SUCCESSOR

ano Therapeutics Private Limited0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
ano Therapeutics Private Limited
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational

Investigators

Sponsor
ano Therapeutics Private Limited

Eligibility Criteria

Inclusion Criteria

  • 1\.Male or female patient who is 18 years and above
  • 2\.Patients undergoing percutaneous coronary intervention with Encruso RAL\-Everolimus Eluting Coronary Stent System
  • 3\.Patient or legal guardian understands the study requirements and provides written informed consent
  • 4\.Patient who is on dual antiplatelet therapy for at least 6 months post procedure

Exclusion Criteria

  • 1\.Patient has known hypersensitivity or allergies to Aspirin, Heparin,Clopidogrel, Ticlopidine, Everolimus or similar drugs, or any other
  • analogue or derivative, cobalt, chromium, or contrast media
  • 2\.Patient with life expectancy less than 2 years
  • 3\.Pregnant and lactating females or planning to become pregnant while in the study
  • 4\.Patient currently participating in another investigational drug or device clinical trial

Outcomes

Primary Outcomes

Not specified

Similar Trials